Clinical study on efficacy and safety of oxaliplatin or tegafur combined with paclitaxel in the treatment of advanced gastric carcinoma
10.13699/j.cnki.1001-6821.2015.08.008
- VernacularTitle:奥沙利铂或替吉奥联合紫杉醇治疗进展期胃癌的临床疗效及安全性评价
- Author:
Chun-Hua ZOU
1
;
Tao-Jin HUANG
;
Yong-Jiu XIE
;
Zheng LIN
;
Yi WANG
;
Hua MING
;
Liang FENG
Author Information
1. 武警部队四川省总队成都医院 肿瘤科
- Keywords:
advanced gastric cancer;
tegafur;
oxaliplatin;
paclitaxel;
clinical efficacy
- From:
The Chinese Journal of Clinical Pharmacology
2015;(8):609-611
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficacy of oxaliplatin or tegafur combined with paclitaxel in the treatment of advanced gastric car-cinoma.Methods Fifty-eight patients with advanced gastric carcino-ma were enrolled in our hospital and divided in two groups .Thirty pa-tients in OP group received the chemotherapy regimen of oxaliplatin 130 mg? m-2 on day 1, and paclitaxel 135 mg? m -2 on day 1 and 8 through intravenous drip and the other 28 subjects in SP group received chemo-therapy regimen of oral tegafur 80 mg? m-2? d-1 on day 1 to day 14 plus paclitaxel 135 mg? m-2 on day 1 and 8 through intravenous drip . The data of clinical efficacy and adverse reactions of the two groups were compared after more than 2 cycles of chemotherapy , twenty-eight days was a cycle.Results The data of objective response rate were 33.3% and 35.7%in OP and SP group , respectively , which indicated that there was no statistical difference between the two groups ( P >0.05 ); but the risk of gradeⅢtoⅣdiarrhea patients in the OP group was much higher than that in SP group (P<0.05).Conclusion The clinical efficacy of oxaliplatin or tegafur combined with paclitaxel in the treatment of advanced gastric carci-noma were both confirmed , but patients who received tegafur combined with paclitaxel will have lower risk of developing adverse reactions .
